Log in
NASDAQ:GBT

Global Blood Therapeutics Stock Forecast, Price & News

$54.67
-0.09 (-0.16 %)
(As of 09/17/2020 12:00 AM ET)
Add
Compare
Today's Range
$53.60
Now: $54.67
$54.79
50-Day Range
$52.76
MA: $62.02
$70.48
52-Week Range
$39.95
Now: $54.67
$87.54
Volume503,640 shs
Average Volume888,887 shs
Market Capitalization$3.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.75
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Read More
Global Blood Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.11 million
Book Value$9.61 per share

Profitability

Net Income$-266,770,000.00

Miscellaneous

Employees171
Market Cap$3.35 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$54.67
-0.09 (-0.16 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

How has Global Blood Therapeutics' stock price been impacted by COVID-19?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GBT shares have decreased by 1.1% and is now trading at $54.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Global Blood Therapeutics?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Global Blood Therapeutics
.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Global Blood Therapeutics
.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.86) EPS for the quarter, beating the Zacks' consensus estimate of ($1.18) by $0.32. The company earned $31.50 million during the quarter, compared to analysts' expectations of $18.85 million.
View Global Blood Therapeutics' earnings history
.

What price target have analysts set for GBT?

22 Wall Street analysts have issued twelve-month price targets for Global Blood Therapeutics' shares. Their forecasts range from $60.00 to $152.00. On average, they anticipate Global Blood Therapeutics' share price to reach $106.71 in the next twelve months. This suggests a possible upside of 96.7% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics
.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Exelixis (EXEL), Square (SQ), Advanced Micro Devices (AMD), Cynosure (CYNO), Gilead Sciences (GILD) and Pfizer (PFE).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 60)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
  • Mr. Peter Radovich, Sr. VP of Operations (Age 41)
  • Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.90%), Perceptive Advisors LLC (9.52%), Vanguard Group Inc. (9.00%), Bank of America Corp DE (8.94%), TimesSquare Capital Management LLC (2.07%) and Goldman Sachs Group Inc. (1.00%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics
.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Federated Hermes Inc., Driehaus Capital Management LLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., State of Wisconsin Investment Board, Nuveen Asset Management LLC, and Point72 Asset Management L.P.. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Dawn Svoronos, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, and Tricia Borga Suvari.
View insider buying and selling activity for Global Blood Therapeutics
.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, TimesSquare Capital Management LLC, Great Point Partners LLC, Marshall Wace North America L.P., First Light Asset Management LLC, Marshall Wace LLP, Neuberger Berman Group LLC, and Bank of America Corp DE.
View insider buying and selling activity for Global Blood Therapeutics
.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $54.25.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $3.33 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.